Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850782 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
NCT03850782 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 515 participants.
The verdict
NCT03850782, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
Study Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Interventions
- DRUG Bimatoprost (SR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2025-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850782
The ClinicalTrials.gov registry entry for NCT03850782 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimatoprost (SR) is the first listed.
NCT03850782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03850782 about?
NCT03850782 is a clinical study titled "Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension". This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medicatio...
What is the current status of trial NCT03850782?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 2019-02-28. Estimated completion is 2025-08-08.
What interventions are being tested in trial NCT03850782?
The interventions under investigation include: Bimatoprost (SR) (DRUG).
Who is sponsoring clinical trial NCT03850782?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.